Is It Time to Reconsider M&A’s Role in Portfolio Building?

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
In the first three quarters of 2019, drug developers pledged to spend $182bn on M&A, beating the last three full year’s annual M&A spend. However, the volume of pharma M&A transactions has actually been falling since 2015, with the number of deals in the first three quarters of 2019 less than half what it was for the same period in 2015.

This session explores current industry M&A trends and their implications for the future landscape, while drawing on the experience of leading dealmakers to understand the role M&A should play in developing a competitive portfolio so companies of all sizes and development stages can make the best strategic decisions.
Editor, Evaluate Vantage
Evaluate Ltd.
Partner and Head of Torreya Europe
Head of Corporate Development and BD Finance, Global Business Development
Takeda Pharmaceutical Company Limited
Chief Strategy Officer
Horizon Therapeutics